Bliss GVS Pharma Limited has informed the Exchange regarding Appointment of Mr Narsimha Shibroor Kamath as Chief Executive Officer of the company w.e.f. September 30, 2025.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma has appointed Mr. Narsimha Shibroor Kamath as its Chief Executive Officer with effect from September 30, 2025. Mr. Kamath is the promoter and founder of the company, having originally acquired Bliss Chemicals & Pharmaceuticals and built it into a business operating in over 60 countries. He is also the father-in-law of the current Managing Director Mr. Gagan Sharma and the father of two Whole-Time Directors, Dr. Vibha Sharma and Mrs. Shruti Rao. The decision was taken at the Board meeting held on September 30, 2025, which ran from 4:15 PM to 5:00 PM.
This is a significant governance change as the promoter-founder is taking direct executive charge as CEO while his close family members already hold key board positions, concentrating decision-making within the founding family. Shareholders may view this positively given his deep knowledge of the business, but governance watchers may note the increased family control at the top.